Compare MGM Resorts International (MGM) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Smith & Nephew plc — how do they compare? MGM Resorts International trades at $29.25 (market cap $7.55B), while Smith & Nephew plc trades at $27.13 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and Smith & Nephew plc for 120 Days on average.
| MGM | SNN | |
|---|---|---|
Market Cap | $7.55B | $11.10B |
Volume | 5,342,346 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $37.17 |
52-Week Low | $30.00 | $26.42 |
Typical Hold Time | 91 Days | 120 Days |
Enterprise Value | $34.85B | $14.13B |
Dividend Yield | 0.03% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $29.77, down 0.77% for the day amid a bearish technical signal and recent deal uncertainty. The stock has faced pressure after Barry Diller's People Inc. withdrew its $48.30 per share acquisition proposal in September 2026, contributing to a 17% decline year-to-date. Fundamentally, revenue grew to $17.54 billion in 2025, but net income margin compressed to 2.4%, while valuation metrics like a P/E of 18.19 and P/S of 0.45 suggest moderate pricing relative to sales. Analyst consensus remains bullish with a $48.75 price target, but technical indicators show selling pressure with key support at $29.
The outlook for MGM hinges on earnings execution and strategic moves, with Q3 2026 results due October 28 offering a near-term catalyst. Risks include volatile cash flows, high debt levels, and integration challenges from potential M&A. The stock's current discount to analyst targets presents opportunity if operational improvements materialize, but investors face headwinds from competitive pressures and macroeconomic sensitivity.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
